The peripheral nervous system is responsible for transmitting signals between the central nervous system (brain and spinal cord) and the rest of the body. In dogs affected by Greyhound Neuropathy, a genetic mutation disrupts normal nerve cell structure and function, leading to gradual deterioration of peripheral nerves. As these nerves become damaged, they lose their ability to properly transmit signals, resulting in progressive muscle weakness and sensory deficits.
Clinical signs of GN typically appear during early to middle adulthood, although the age of onset and severity may vary between individuals. Early symptoms may include subtle weakness, reduced exercise tolerance, and occasional stumbling or incoordination. As the condition progresses, affected dogs may develop more noticeable gait abnormalities, muscle wasting, tremors, difficulty standing, and loss of reflexes. Some dogs may also experience reduced sensation in the limbs, making them less responsive to touch or pressure. Over time, mobility becomes increasingly impaired, and severe cases may result in significant physical disability.
The GN DNA Health Test is designed to identify the specific genetic mutation associated with Greyhound Neuropathy. Testing is simple, safe, and non-invasive, typically requiring a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine the dog's genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including before clinical symptoms appear.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the GN mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing Greyhound Neuropathy.
Genetic testing for GN provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that help reduce the prevalence of the disorder while maintaining healthy genetic diversity within the breed population. Avoiding carrier-to-carrier matings significantly reduces the risk of producing affected puppies.
For dog owners, understanding a dog’s genetic status allows for proactive neurological monitoring and early supportive care. Dogs identified as at risk may benefit from regular veterinary evaluations, physical therapy, and environmental adjustments to support mobility and comfort. While there is currently no cure for Greyhound Neuropathy, supportive management can help maintain quality of life for as long as possible.
The Greyhound Neuropathy (GN) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited peripheral nerve disorder in future generations.
